ArriVent BioPharma
- Market cap
- 832.81M
- P/E (TTM)i
- -4.76
- P/Bi
- 2.27
- EPSi
- -4.32
- Div yieldi
- 0.00%
- 52W posi
- 23%
Anonymous reader poll. Unscientific, not investment advice.
ArriVent BioPharma ended the session at 16.89, up 11.93%. Its market capitalisation is about 832.81M, the #3057 most valuable US-listed company we track. Across 8 analysts the consensus rating is Buy, with an average price target of 44.57 (+164%). The shares sit 23% of the way up their 52-week range of 11.36 to 35.83.
✦ StockVane Quant Insights how this is computed
- Below its 200-day average or in the bottom third on momentum — the strategy is out of it.
- Signal has read SELL for 2 days.
- Recent price momentum is -31.6% on average (3-month/1-year).
- Main-fund capital flow has been a net inflow over the last 45 sessions.
- Short interest has risen to 17.8% of float.
- Analyst tilt is Buy.
- Price is below its 20-day average and below its 60-day average.
- The 20-day average is below the 60-day average, a short-term downtrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 977 U.S. stocks StockVane covers.
Valuation N/A
How expensive the stock is versus earnings, sales and its own 5-year history.
Not enough data to grade this factor.
Growth N/A
How fast revenue, profit and free cash flow are compounding.
Not enough data to grade this factor.
Profitability F
How much profit the business keeps from each dollar of sales and capital.
| Return on equity | -58.9% | Better than 3% |
| Return on invested capital | -62.8% | Better than 1% |
Momentum B-
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | -16.7% | Better than 15% |
| 6-month return | 13.0% | Better than 62% |
| 12-month return (ex latest month) | 55.1% | Better than 83% |
| Distance below 52-week high | 20.6% | Better than 46% |
Financial Health A+
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 12.8x | Better than 98% |
| Debt to assets | 0.0% | Better than 100% |
Analyst View A
What the Street thinks: share of Buy ratings and upside to the average target.
| Analysts rating Buy | 100.0% | Better than 80% |
| Upside to average target | 56.6% | Better than 86% |
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector, so capital-light software tends to grade lower there than utilities. Recomputed every 6 hours from our market data. Not investment advice, and not tailored to your financial situation, goals, or risk tolerance.
Price chart
Performance
Key statistics
Price & volume
- Prev close
- 15.09
- Open
- 15.25
- Day range
- 14.97 - 17.35
- Avg price
- 16.50
- Volume
- 4.33M
- Turnover
- 71.53M
- Turnover ratei
- 13.50%
- Volume ratioi
- 0.98
- Amplitudei
- 15.75%
- 52-week rangei
- 11.36 - 35.83
Valuation
- P/Ei
- -3.91
- P/E (TTM)i
- -4.76
- P/Bi
- 2.27
- EPSi
- -4.32
- Book value / shi
- 7.44
- Net profit
- -213.01M
- Net assets
- 366.85M
Share structure
- Market cap
- 832.81M
- Float capi
- 542.27M
- Shares out
- 49.31M
- Float sharesi
- 32.11M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 2024-01-26
52.9% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
+12.64M net over the window
Short interest
- Shares short
- 8.77M
- % of floati
- 17.78%
- Days to coveri
- 17.69
- As of
- 2026-09-15
Frequently asked questions
What is the current stock price of ArriVent BioPharma (AVBP)?
ArriVent BioPharma last traded at 16.89. The quote on this page refreshes every few seconds while US markets are open.
What is ArriVent BioPharma's market cap?
About 832.81M.
What is the P/E ratio of ArriVent BioPharma?
The trailing twelve-month P/E is -4.76. The Valuation tab shows it against the stock's own five-year range.
Does ArriVent BioPharma pay a dividend?
ArriVent BioPharma does not currently pay a regular dividend.
Is ArriVent BioPharma a buy according to analysts?
The consensus of 8 analysts is a Buy rating, with an average 12-month price target of 44.57, which implies 163.9% upside from the current price. This is not investment advice.
What is ArriVent BioPharma's StockVane Quant Rating?
The StockVane Momentum strategy currently rates ArriVent BioPharma a D (Sell). Below its 200-day average or in the bottom third on momentum — the strategy is out of it. Not investment advice.
Quote time 2026-10-08 08:15:47 · For reference only, not investment advice and not tailored to your situation.